Jovana Nikolic is an Assistant Editor with a focus on medical and scientific research. Her work has been featured in publications such as KALTBLUT and Infectious Disease Advisor. Jovana's articles cover a range of topics including clinical trials, disease management, and breakthrough discoveries in the field of medicine.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jovana Nikolic's articles primarily focus on medical research, clinical trials, genetic disorders, rare diseases, and treatment options. She often cites data and uses press releases as sources.
Given her focus on these areas, pitches should provide insights into recent medical research findings, updates on ongoing or upcoming clinical trials for rare diseases or genetic disorders. Additionally, experts with a deep understanding of the development of novel treatments would likely capture Jovana’s interest.
As she does not have a specified geographic focus but covers topics that are global in nature (medical research and clinical trials), relevant information from any location could be suitable for her coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) may have more advanced left atrial structural and functional remodeling rates
The phase 3, randomized, double-blind, VITALIZE study will assess the efficacy and safety of riliprubart vs intravenous immunoglobulin (IVIG) in
A variety of autoantibodies might be produced in membranous nephropathy accompanied by anti-contactin 1 (CNTN1) antibody-associated chronic inflammatory
A real-world, prospective, noninterventional, multinational cohort study that will evaluate the long-term safety of inotersen (Tegsedi ® ) in patients with transthyretin amyloid polyneuropathy (ATTR-PN) is currently recruiting.
A cross-sectional, observational, cohort study that will phenotype and characterize Danish wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is currently recruiting.
A new phase 2, open-label, multicenter, single-arm study set to assess the long-term safety and tolerability of repeat-dose OMS906 administration
A new case report published in Hematology Reports suggests there could be a correlation between systemic mastocytosis (SM) associated with a hematological neoplasm and acquired factor VII (FVII) deficiency.
Which of the statements below about the testing for hemolytic disease of the fetus and newborn (HDFN) are correct?
A new open-label, interventional, single-group assessment trial will determine red blood cell (RBC) survival in patients with sickle cell disease (SCD) and other hemoglobinopathies using biotin labeling.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Promising Innovative Medicine (PIM) designation for sebetralstat
(833) 317-6278 
